drugmakers to join forces to make millions of ebola vaccine doses
Last Updated : GMT 05:17:37
Emiratesvoice, emirates voice
Emiratesvoice, emirates voice
Last Updated : GMT 05:17:37
Emiratesvoice, emirates voice

Drugmakers to join forces to make millions of Ebola vaccine doses

Emiratesvoice, emirates voice

Emiratesvoice, emirates voice Drugmakers to join forces to make millions of Ebola vaccine doses

A handout picture released by the World Health
London - Arab Today

Leading drugmakers plan to work together to speed up the development of an Ebola vaccine and hope to produce millions of doses for use next year.

US firm Johnson & Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain’s GlaxoSmithKline, which is working on a rival vaccine.

The economics of an Ebola vaccine are still unclear but drug companies with an eye on their reputations are under pressure to respond to the major international health crisis now ravaging one of the poorest corners of Africa.

J&J’s head of research Paul Stoffels said it was important to have several experimental vaccine candidates in development, since it is not clear which ones will work, but resources could in future be focused on one clear winner.

GSK’s chief executive Andrew Witty told reporters on Wednesday that a meeting of experts in Geneva this week would discuss ways to ensure that all companies, including those with no direct involvement in the Ebola work, pulled together to help remove supply bottlenecks.

There is currently no proven vaccine against the deadly disease and drug companies have been wary in the past of pouring resources into Ebola since previous outbreaks have been small.

As a result much of the research effort to date has been driven not by concerns about sporadic outbreaks in Africa but by fears in the West that Ebola might become a bioterror weapon.

Clinical tests on GSK’s vaccine and another from NewLink Genetics are under way, while human tests on J&J’s vaccine will start in January.

The World Health Organisation (WHO) hopes that tens of thousands of people in West Africa, including frontline health care workers, can start receiving Ebola vaccines from January as part of large-scale clinical trials.

The first doses of GSK’s Ebola vaccine are expected to be ready late this year. “It will give WHO and other agencies a useful tool,” Witty said, adding that the GSK product was likely to be the first vaccine to be deployed on a limited basis.

Witty and Stoffels said they had talked several times in recent days about collaboration, including swapping ideas on production and vaccine development. “It might even be that we have to combine their vaccine with ours,” Stoffels said.

J&J expects the accelerated work on its Ebola vaccine, which has been helped by recent advances in technology, would yield 250,000 doses by May.

The US company plans to test its vaccine for safety and immune response in healthy volunteers in Europe, the United States and Africa from early January, having committed up to $200 million (Dh734 million) to accelerate the programme.

West Africa’s Ebola outbreak began in March and has killed more than 4,500 people, most of them in Liberia, Sierra Leone and Guinea, according to the WHO. Outbreaks in Senegal and Nigeria have been declared over by the WHO and there have been a handful of cases in Spain and the United States.

The J&J vaccine was discovered in collaboration with the US National Institutes of Health (NIH) and includes technology from Denmark-based Bavarian Nordic, which will now receive a cash injection from the American health care company.

The total potential deal value for Bavarian Nordic could be more than $187 million, including up-front payments, milestone payments based on product progress, a supply contract and the purchase by J&J of shares in the Danish biotech business.

Bavarian Nordic’s share price jumped 23 per cent to 185 Danish crowns after the announcement of J&J’s plans.

J&J has simplified and fast-tracked its vaccine programme in the light of the world’s worst Ebola outbreak.

It had been working to develop a vaccine against both the Zaire and Sudan strains of Ebola, as well as a related condition called Marburg disease. However, it is now also developing a vaccine targeting only the Zaire strain behind the current epidemic, which should yield results faster.

Although the safety and effectiveness of J&J’s and other experimental vaccines has yet to be proven, they have provided good protection against the Zaire strain of Ebola when tested on macaque monkeys, which is seen as a promising sign that they are likely to work in humans.

Like a number of experimental vaccines against various diseases, J&J’s vaccine uses a common cold virus, called an adenovirus, to carry its payload.

Immunisation with the J&J vaccine, which was developed by its Crucell unit in the Netherlands, consists of two injections: one to prime the immune system and a second to boost the response. In contrast, researchers are testing a single shot of GSK’s vaccine

source : gulfnews

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

drugmakers to join forces to make millions of ebola vaccine doses drugmakers to join forces to make millions of ebola vaccine doses

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

drugmakers to join forces to make millions of ebola vaccine doses drugmakers to join forces to make millions of ebola vaccine doses

 



GMT 05:17 2024 Wednesday ,07 February

Amazon to open first cashierless shop

GMT 19:58 2017 Wednesday ,02 August

Emirates Airline celebrates 9 years of A380 service

GMT 10:17 2014 Monday ,13 October

Latin America universities fail to make grade

GMT 19:53 2017 Wednesday ,18 January

Afghan security forces kill 6 Daesh militants in raids

GMT 00:15 2011 Friday ,15 April

New Syrian PM forms government

GMT 15:41 2011 Saturday ,15 October

YouTube signs video content deals

GMT 03:11 2017 Friday ,17 February

US says Libya close to eliminating Daesh from Sirte

GMT 04:49 2015 Friday ,03 April

Kenya government: University operation is over

GMT 15:36 2011 Thursday ,21 April

Ugandan police arrest opposition leader

GMT 15:38 2016 Thursday ,23 June

1st Saudi-built Renault truck rolls out of KAEC

GMT 17:56 2018 Wednesday ,17 January

France coach defends Bastareaud over homophobia

GMT 22:09 2017 Tuesday ,23 May

Right mentor is key to your success

GMT 14:00 2017 Thursday ,14 December

Hayek details harrowing ordeal

GMT 16:28 2017 Wednesday ,15 November

IS corpses in Libya await fate in containers

GMT 09:55 2017 Wednesday ,25 October

Einstein note on modest living sells for $1.56 million

GMT 08:09 2017 Wednesday ,06 December

Afro hair beauty service

GMT 00:27 2017 Wednesday ,04 October

Saif bin Zayed receives Bahraini Interior Minister
Emiratesvoice, emirates voice
 
 Emirates Voice Facebook,emirates voice facebook  Emirates Voice Twitter,emirates voice twitter Emirates Voice Rss,emirates voice rss  Emirates Voice Youtube,emirates voice youtube  Emirates Voice Youtube,emirates voice youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

emiratesvoieen emiratesvoiceen emiratesvoiceen emiratesvoiceen
emiratesvoice emiratesvoice emiratesvoice
emiratesvoice
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
emiratesvoice, Emiratesvoice, Emiratesvoice